Yu CAO
About Yu CAO
Yu Cao is a Principal Scientist at Tessera Therapeutics, specializing in lipid nanoparticle delivery systems for gene therapies. With over a decade of experience in immuno-oncology and related fields, he has held various research roles in notable organizations.
Work at Tessera Therapeutics
Yu Cao has been serving as Principal Scientist at Tessera Therapeutics since 2023. In this role, he focuses on the development of proof-of-concept studies for the company's gene writing and rewriting modalities. His work involves leading initiatives that utilize lipid nanoparticle (LNP) delivery systems for innovative gene and cell therapies. Located in Cambridge, Massachusetts, he collaborates with various early-stage and preclinical departments to advance therapeutic programs.
Previous Experience in Pharmaceuticals
Prior to his current position, Yu Cao worked at Agios Pharmaceuticals as a Scientist from 2020 to 2022. He also held the role of Senior Scientist at Tessera Therapeutics for one year, from 2022 to 2023. His career includes a significant tenure at Moffitt Cancer Center, where he served as a Research Scientist from 2017 to 2019, and a postdoctoral researcher position at Augusta University from 2014 to 2017.
Education and Expertise
Yu Cao holds a Doctor of Philosophy (PhD) in Molecular Immunology from The Academy of Military Science. He also earned a Master of Science (MS) in Infection and Immunity from the University of Sydney and a Bachelor of Science (BS) in Biotechnology from Sichuan University. Additionally, he is pursuing further education in Team Management and Leadership at Harvard Business School Online. His expertise includes mechanism of action (MoA) and biomarker identification in preclinical research.
Research and Development Background
With over a decade of experience in research and development, Yu Cao specializes in the fields of immuno-oncology, oncology, and hematology. He has demonstrated a strong capability in developing lipid nanoparticle (LNP) delivery systems for gene and cell therapies. His work is characterized by cross-functional collaboration with multiple departments to enhance therapeutic programs.